首頁 >> 供求商機(jī)
貨物所在地:廣東廣州市
更新時(shí)間:2025-01-16 21:00:07
瀏覽次數(shù):320
在線詢價(jià)收藏產(chǎn)品( 聯(lián)系我們,請(qǐng)說明是在 化工儀器網(wǎng) 上看到的信息,謝謝?。?/p>
歐盟玩具安全新指令2009/48/EC 相關(guān)致敏性香味劑標(biāo)準(zhǔn)品
Sigma-Aldrich試劑及標(biāo)準(zhǔn)品
食品相關(guān)檢測標(biāo)準(zhǔn)品-維生素/色素/脂肪酸甲酯等
工業(yè)品檢測-偶氮染料/鄰苯二甲酸酯/有機(jī)錫/多溴聯(lián)苯/多溴聯(lián)苯醚/多氯聯(lián)苯
農(nóng)藥標(biāo)準(zhǔn)品-有機(jī)氯/有機(jī)磷/菊酯類
獸藥標(biāo)準(zhǔn)品-孔雀石綠/硝基呋喃/四環(huán)素/磺胺等
美國ChromaDex天然提取物標(biāo)準(zhǔn)品
美國Medical ISO藥物異構(gòu)體標(biāo)準(zhǔn)品
CIL異構(gòu)體/同位素標(biāo)準(zhǔn)品
Chiron異構(gòu)體/同位素標(biāo)準(zhǔn)品
ADENINE (Ade) [6-aminopurine]
MW 135.13; crystalline; purity > 98% (HPLC) | ||
R:22, S:26, 36; CAS:73-24-5; C5H5N5 | ||
![]() | ||
001 0241 | 5 | g |
001 0242 | 25 | g |
001 0243 | 100 | g |
001 0244 | 500 | g |
ADENINE HYDROCHLORIDE (Ade.HCl) [6-aminopurine hydrochloride]
MW 171.59; crystalline; purity > 98% (HPLC) | ||
R:22, S:26, 36; CAS: 2922-28-3; C5H5N5.HCl | ||
water soluble | ||
![]() | ||
001 3261 | 5 | g |
001 3262 | 25 | g |
001 3263 | 100 | g |
ADENINE HEMISULFATE (Ade.1/2H2SO4) [6-aminopurine hemisulfate]
MW 184.17; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 321-30-2; C5H5N5.1/2H2SO4 | ||
![]() | ||
001 3271 | 5 | g |
001 3272 | 25 | g |
001 3273 | 100 | g |
ADENOSINE (Ado) [6-amino-9-β-D-ribofuranosylpurine]
MW 267.25; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 58-61-7; C10H13N5O4 | ||
![]() | ||
001 6301 | 5 | g |
001 6302 | 25 | g |
001 6303 | 100 | g |
001 6304 | 500 | g |
N6-BENZYLADENINE (BA) [6 - benzylaminopurine]
MW 225.25; crystalline; purity > 98% (HPLC) | ||
R:36/37/38, S:26, 36; CAS: 1214-39-7; C12H11N5 | ||
![]() | ||
001 0221 | 1 | g |
001 0222 | 5 | g |
001 0223 | 25 | g |
001 0224 | 100 | g |
N6-BENZYLADENINE HYDROCHLORIDE (BA.HCl) [6 - benzylaminopurine hydrochloride]
MW 261.71; crystalline; purity > 98% (HPLC) | ||
R:36/37/38, S:26, 36; CAS: 162714-86-5; C12H11N5.HCl | ||
water soluble | ||
![]() | ||
001 0181 | 250 | mg |
001 0182 | 1 | g |
001 0183 | 5 | g |
N6-BENZYLADENOSINE (BAR) [6-benzylamino-9-β-D-ribofuranosylpurine]
MW 357.37; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 4294-16-0; C17H19N5O4 | ||
![]() | ||
001 0551 | 100 | mg |
001 0552 | 250 | mg |
001 0553 | 1 | g |
001 0554 | 5 | g |
N6-BENZYLADENINE-3-GLUCOSIDE (BA3G) [6-benzylamino-3-β-D-glucopyranosylpurine]
MW 387.40; crystalline; purity > 95% (HPLC ) | ||
S:26, 36; CAS: 56159-41-2; C18H21N5O5 | ||
![]() | ||
001 0581 | 1 | mg |
001 0582 | 2 | mg |
001 0583 | 5 | mg |
N6-BENZYLADENINE-7-GLUCOSIDE (BA7G) [6-benzylamino-7-β-D-glucopyranosylpurine]
MW 387.40; crystalline; purity > 95% (HPLC ) | ||
S:26, 36; CAS: 56159-42-3; C18H21N5O5 | ||
![]() | ||
001 0571 | 1 | mg |
001 0572 | 2 | mg |
001 0573 | 5 | mg |
N6-BENZYLADENINE-9-GLUCOSIDE (BA9G) [6-benzylamino-9-β-D-glucopyranosylpurine]
MW 387.40; crystalline; purity > 95% (HPLC ) | ||
R: 36/37/38, S: 26, 36; CAS: 4294-17-1; C18H21N5O5 | ||
![]() | ||
001 3281 | 1 | mg |
001 3282 | 2 | mg |
001 3283 | 5 | mg |
N6-BENZYL-9-(2-TETRAHYDROPYRANYL)ADENINE (BPA)
MW 309.37; crystalline; purity > 98% (HPLC ) | ||
R:22, S: 26,36; CAS: 2312-73-4; C17H19N5O | ||
![]() | ||
001 3291 | 100 | mg |
001 3292 | 500 | mg |
001 3293 | 1 | g |
001 3294 | 5 | g |
001 3295 | 25 | g |
N6 - BENZYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (BAMP) [6-benzylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 499.34; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 13484-66-7; C17H18N5Na2O7P.H2O | ||
![]() | ||
001 5001 | 1 | mg |
001 5002 | 2 | mg |
001 5003 | 5 | mg |
N-(2-CHLORO-4-PYRIDYL)-N'-PHENYLUREA (CPPU,4-CPPU)
MW 247.69; crystalline; purity > 98% (HPLC) | ||
R:36/37, S: 26, 36; CAS: 68157-60-8; C10H12ClN3O | ||
![]() | ||
001 0191 | 100 | mg |
001 0192 | 250 | mg |
001 0193 | 1 | g |
N6 - CYCLOPENTYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (MP) [6-cyclopentylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 459.31; CRYSTALLINE; purity > 97% (HPLC) | ||
S:26, 36; CAS: 117778-38-8; C15H20N5Na2O7P.H2O | ||
![]() | ||
001 6261 | 1 | mg |
001 6262 | 2 | mg |
001 6263 | 5 | mg |
DIHYDROZEATIN (DZ) [6-(4-hydroxy-3-methylbutylamino)purine]
MW 221.26; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 14894-18-9; C10H15N5O | ||
![]() | ||
001 0601 | 5 | mg |
001 0602 | 10 | mg |
001 0603 | 50 | mg |
001 0604 | 250 | mg |
001 0605 | 1 | g |
DIHYDROZEATIN HYDROCHLORIDE (DZ.HCl) [6-(4-hydroxy-3-methylbutylamino)purine hydrochloride]
MW 257.72; crystalline; purity > 98% (HPLC) | ||
R:22, S:26, 36; CAS: 1402800-82-1; C10H15N5O.HCl | ||
water soluble | ||
![]() | ||
001 0251 | 10 | mg |
001 0252 | 50 | mg |
001 0253 | 250 | mg |
DIHYDROZEATIN RIBOSIDE (DZR) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosylpurine]
MW 353.38; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 22663-55-4; C15H23N5O5 | ||
![]() | ||
001 0611 | 5 | mg |
001 0612 | 10 | mg |
001 0613 | 50 | mg |
001 0614 | 250 | mg |
001 0615 | 1 | g |
DIHYDROZEATIN-7-GLUCOSIDE (DZ7G) [6-(4-hydroxy-3-methylbutylamino)-7-β-D-glucopyranosylpurine]
MW 383.41; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 91599-03-0; C16H25N5O6 | ||
![]() | ||
001 0621 | 1 | mg |
001 0622 | 2 | mg |
001 0623 | 5 | mg |
DIHYDROZEATIN-9-GLUCOSIDE (DZ9G) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-glucopyranosylpurine]
MW 383.41; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 73263-99-7; C16H25N5O6 | ||
![]() | ||
001 0631 | 1 | mg |
001 0632 | 2 | mg |
001 0633 | 5 | mg |
DIHYDROZEATIN-O-GLUCOSIDE (DZOG) [6-(4-β-D-glucopyranosyloxy-3-methylbytylamino)purine]
MW 383.41; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 62512-96-3; C16H25N5O6 | ||
![]() | ||
001 0641 | 1 | mg |
001 0642 | 2 | mg |
001 0643 | 5 | mg |
DIHYDROZEATIN-O-GLUCOSIDE RIBOSIDE (DZROG) [6-(4-β-D-glucopyranosyloxy-3-methylbutyl)amino-9-β-D-purine ribofuranosyl]
MW 515.52; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 62512-95-2; C21H33N5O10 | ||
![]() | ||
001 0651 | 1 | mg |
001 0652 | 2 | mg |
001 0653 | 5 | mg |
DIHYDROZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (DZRMP) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosyl purine-5'-monophosphate disodium monohydrate]
MW 495.34; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 31284-94-3; C15H22N5Na2O8P.H2O | ||
![]() | ||
001 5011 | 1 | mg |
001 5012 | 2 | mg |
001 5013 | 5 | mg |
DIHYDROZEATIN-O-ACETYL (AcDZ) [6-(4-acetoxy-3-methylbutylamino)purine]
MW 263.30; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 126221-88-3; C12H17N5O2 | ||
![]() | ||
001 5021 | 5 | mg |
001 5022 | 10 | mg |
001 5023 | 50 | mg |
N6-(3-FLUOROBENZYL)ADENINE (mFBA) [6 - (3-fluorobenzylamino)purine]
MW 243.25; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 525608-36-0; C12H10FN5 | ||
![]() | ||
001 5801 | 100 | mg |
001 5802 | 500 | mg |
001 5803 | 1 | g |
N6-(3-FLUOROBENZYL)ADENOSINE (mFBAR)[6-(3-fluorobenzylamino)-9-β-D-ribofuranosylpurine]
MW 375.36; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 29204-64-6; C17H18FN5O4 | ||
![]() | ||
001 5811 | 100 | mg |
001 5812 | 500 | mg |
001 5813 | 1 | g |
001 5814 | 5 | g |
HYPOXANTHINE (Hyp) [6-hydroxypurine]
MW 136.11; crystalline; purity > 98% ( HPLC ) | ||
S:26, 36; CAS: 68-94-0; C5H4N4O | ||
![]() | ||
001 5941 | 5 | g |
001 5942 | 25 | g |
001 5943 | 100 | g |
N6-ISOPENTENYLADENINE (iP) [6-(3,3-dimethylallylamino)purine]
MW 203.25; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 2365-40-4; C10H13N5 | ||
![]() | ||
001 0161 | 1 | g |
001 0162 | 5 | g |
001 0163 | 10 | g |
001 0164 | 25 | g |
N6-ISOPENTENYLADENINE HYDROCHLORIDE (iP.HCl) [6-(3,3-dimethylallylamino)purine hydrochloride]
MW 239.71; crystalline; purity > 98% (HPLC) | ||
R:22, S:26, 36; CAS: 177966-67-5; C10H13N5.HCl | ||
water soluble | ||
![]() | ||
001 5031 | 1 | g |
001 5032 | 5 | g |
001 5033 | 10 | g |
N6-ISOPENTENYLADENOSINE (iPR) [6-(3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]
MW 335.37; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 7724-76-7; C15H21N5O4 | ||
![]() | ||
001 0171 | 100 | mg |
001 0172 | 250 | mg |
001 0173 | 1 | g |
2-BENZYLTHIO-N6-ISOPENTENYLADENINE (2BSiP)[2-benzylthio-6-(3,3-dimethylallylamino)purine]
MW 325.44; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 52172-11-9; C17H19N5S | ||
![]() | ||
001 5241 | 5 | mg |
001 5242 | 10 | mg |
001 5243 | 50 | mg |
2-METHYLTHIO-N6-ISOPENTENYLADENINE (2MeSiP) [2-methylthio-6-(3,3-dimethylallylamino)purine]
MW 249.34; crystalline; purity > 98% (HPLC) | ||
S:23, 36; CAS: 20758-33-2; C11H15N5S | ||
![]() | ||
001 5071 | 1 | mg |
001 5072 | 2 | mg |
001 5073 | 5 | mg |
2-METHYLTHIO-N6-ISOPENTENYLADENOSINE (2MeSiPR) [2-methylthio-6-(3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]
MW 381.46; CRYSTALLINE; purity > 95% (HPLC) | ||
S:26, 36; CAS: 20859-00-1; C16H23N5O4S | ||
![]() | ||
001 5061 | 1 | mg |
001 5062 | 2 | mg |
001 5063 | 5 | mg |
2-MERCAPTO-N6-ISOPENTENYLADENINE (2SiP) [2-mercapto-6-(3,3-dimethylallylamino)purine]
MW 235.31; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 52172-12-0; C10H13N5S | ||
![]() | ||
001 5081 | 1 | mg |
001 5082 | 2 | mg |
001 5083 | 5 | mg |
N6-ISOPENTENYLADENINE-3-GLUCURONIDE (iP3GN)
MW 379.38; CRYSTALLINE; purity > 97% (HPLC) | ||
S:26, 36; CAS: 147663-48-7; C16H21N5O6 | ||
![]() | ||
001 5981 | 5 | mg |
001 5982 | 25 | mg |
001 5983 | 50 | mg |
N6-ISOPENTENYLADENINE-3-GLUCURONIDE amide (iP3GNA)
MW 378.39; CRYSTALLINE; purity > 98% (HPLC) | ||
S:26, 36; CAS: NONE; C16H22N6O5 | ||
![]() | ||
001 5991 | 5 | mg |
001 5992 | 25 | mg |
001 5993 | 50 | mg |
N6-ISOPENTENYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (iPMP) [6-(3,3-dimethylallylamino)-9-b-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 477.33; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 20268-93-3; C15H20N5Na2O7P.H2O | ||
![]() | ||
001 5041 | 1 | mg |
001 5042 | 2 | mg |
001 5043 | 5 | mg |
N6-ISOPENTENYLADENINE-7-GLUCOSIDE (iP7G) [6-(3,3-dimethylallylamino)-7-β-D-glucopyranosylpurine]
MW 365.39; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 59384-58-6; C16H23N5O5 | ||
![]() | ||
001 5051 | 1 | mg |
001 5052 | 2 | mg |
001 5053 | 5 | mg |
N6-ISOPENTENYLADENINE-9-GLUCOSIDE (iP9G) [6-(3,3-dimethylallylamino)-9-β-D-glucopyranosylpurine]
MW 365.39; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 83087-94-9; C16H23N5O5 | ||
![]() | ||
001 0231 | 1 | mg |
001 0232 | 2 | mg |
001 0233 | 5 | mg |
KINETIN (K) [6-furfurylaminopurine]
MW 215.22; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 525-79-1; C10H9N5O | ||
![]() | ||
001 0341 | 250 | mg |
001 0342 | 1 | g |
001 0343 | 5 | g |
001 0344 | 25 | g |
KINETIN HYDROCHLORIDE(K.HCl) [6-furfurylaminopurine hydrochloride]
MW 251.68; crystalline; purity > 98% (HPLC) | ||
R:22, S:26, 36; CAS: 177966-68-6; C10H9N5O.HCl | ||
water soluble | ||
![]() | ||
001 0261 | 100 | mg |
001 0262 | 500 | mg |
001 0263 | 1 | g |
KINETIN RIBOSIDE (KR) [6 - furfurylamino-9-b-D-ribofuranosylpurine]
MW 347.33; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 4338-47-0; C15H17N5O5 | ||
![]() | ||
001 0351 | 100 | mg |
001 0352 | 250 | mg |
001 0353 | 1 | g |
001 0354 | 5 | g |
KINETIN-3-GLUCOSIDE (αK3G) [6-furfurylamino-3-α-D-glucopyranosylpurine]
MW 377.36; crystalline; purity > 95% (HPLC ) | ||
S:26, 36; CAS: 900786-14-3; C16H19N5O6 | ||
![]() | ||
001 5771 | 1 | mg |
001 5772 | 2 | mg |
001 5773 | 5 | mg |
KINETIN-9-GLUCOSIDE (K9G) [6-furfurylamino-9-β-D-glucopyranosylpurine]
MW 377.36; crystalline; purity > 95% (HPLC ) | ||
S:26, 36; CAS: 98177-43-6; C16H19N5O6 | ||
![]() | ||
001 0441 | 1 | mg |
001 0442 | 2 | mg |
001 0443 | 5 | mg |
KINETIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (KMP) [6-furfurylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 489.30; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 13484-67-8; C15H16N5Na2O8P.H2O | ||
![]() | ||
001 5091 | 1 | mg |
001 5092 | 2 | mg |
001 5093 | 5 | mg |
PHENYLADENINE [6-phenylaminopurine, 6-anilinopurine]
MW 211.23; crystalline; purity > 95% (HPLC) | ||
R:36/37/38; S:26, 36; CAS:1210-66-8; C11H9N5 | ||
![]() | ||
001 6971 | 100 | mg |
001 6972 | 500 | mg |
001 6973 | 1 | g |
MSDS |
THIDIAZURON (TDZ) [N-phenyl-N'-(1,2,3-thiadiazol-5-yl)urea]
MW 220.25; crystalline; purity > 98% (HPLC ) | ||
R:36/37/38, S:22, 26, 36; CAS: 51707-55-2; C9H8N4OS | ||
![]() | ||
001 3161 | 5 | mg |
001 3162 | 25 | mg |
001 3163 | 250 | mg |
001 3164 | 1 | g |
001 3165 | 5 | g |
meta-TOPOLIN (mT) [6-(3-hydroxybenzylamino)purine]
MW 241.25; crystalline; purity >99% (HPLC) | ||
S:26, 36; CAS: 75737-38-1; C12H11N5O | ||
![]() | ||
001 0101 | 100 | mg |
001 0102 | 500 | mg |
001 0103 | 1 | g |
001 0104 | 5 | g |
001 0105 | 25 | g |
meta-TOPOLIN RIBOSIDE (mTR) [6-(3-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
MW 373.37; crystalline;purity >99% (HPLC) | ||
S:26, 36; CAS: 110505-76-5; C17H19N5O5 | ||
![]() | ||
001 0111 | 100 | mg |
001 0112 | 500 | mg |
001 0113 | 1 | g |
meta-TOPOLIN-9-GLUCOSIDE (mT9G) [6-(3-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 403.40; crystalline; purity >95% (HPLC) | ||
S:26, 36; CAS: 179528-30-4; C18H21N5O6 | ||
![]() | ||
001 0141 | 1 | mg |
001 0142 | 2 | mg |
001 0143 | 5 | mg |
meta-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (mTMP) [6-(3-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 515.34; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 946853-27-6; C17H18N5Na2O8P.H2O | ||
![]() | ||
001 6841 | 1 | mg |
001 6842 | 2 | mg |
001 6843 | 5 | mg |
ortho-TOPOLIN (oT) [6-(2-hydroxybenzylamino)purine]
MW 241.25; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 20366-83-0; C12H11N5O | ||
![]() | ||
001 0121 | 100 | mg |
001 0122 | 500 | mg |
001 0123 | 1 | g |
ortho-TOPOLIN RIBOSIDE (oTR)[6-(2-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
MW 373.37; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 50868-58-1; C17H19N5O5 | ||
![]() | ||
001 0131 | 100 | mg |
001 0132 | 500 | mg |
001 0133 | 1 | g |
ortho-TOPOLIN-9-GLUCOSIDE (oT9G) [6-(2-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 403.40; crystalline; purity >95% (HPLC) | ||
S:26, 36; CAS: 160299-96-7; C18H21N5O6 | ||
![]() | ||
001 0151 | 1 | mg |
001 0152 | 2 | mg |
001 0153 | 5 | mg |
ortho-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (oTMP) [6-(2-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 515.34; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 1242061-01-3; C17H18N5Na2O8P.H2O | ||
![]() | ||
001 6831 | 1 | mg |
001 6832 | 2 | mg |
001 6833 | 5 | mg |
para-TOPOLIN (pT) [6-(4-hydroxybenzylamino)purine]
MW 241.25; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 80054-30-4; C12H11N5O | ||
![]() | ||
001 0451 | 100 | mg |
001 0452 | 500 | mg |
001 0453 | 1 | g |
para-TOPOLIN RIBOSIDE (pTR) [6-(4-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
MW 373.37; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 23666-24-2; C17H19N5O5 | ||
![]() | ||
001 0461 | 100 | mg |
001 0462 | 500 | mg |
001 0463 | 1 | g |
para-TOPOLIN-9-GLUCOSIDE (pT9G) [6-(4-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 403.40; crystalline; purity >95% (HPLC) | ||
S:26, 36; CAS: 1046433-04-8; C18H21N5O6 | ||
![]() | ||
001 0401 | 1 | mg |
001 0402 | 2 | mg |
001 0403 | 5 | mg |
para-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (pTMP) [6-(3-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 515.34; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 1402800-77-4; C17H18N5Na2O8P.H2O | ||
![]() | ||
001 6851 | 1 | mg |
001 6852 | 2 | mg |
001 6853 | 5 | mg |
ortho-METHOXYTOPOLIN (MeoT) [6-(2-methoxybenzylamino)purine]
MW 255.28; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 75737-41-6; C13H13N5O | ||
![]() | ||
001 0491 | 100 | mg |
001 0492 | 500 | mg |
001 0493 | 1 | g |
ortho-METHOXYTOPOLIN RIBOSIDE (MeoTR) [6-(2-methoxybenzylamino)-9-β-D-ribofuranosylpurine]
MW 387.40; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 23660-98-2; C18H21N5O5 | ||
![]() | ||
001 0501 | 100 | mg |
001 0502 | 500 | mg |
001 0503 | 1 | g |
ortho-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(2-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 417.43; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 1226978-27-7; C19H23N5O6 | ||
![]() | ||
001 5861 | 1 | mg |
001 5862 | 2 | mg |
001 5863 | 5 | mg |
meta-METHOXYTOPOLIN (MemT) [6-(3-methoxybenzylamino)purine]
MW 255.28; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 75737-39-2; C13H13N5O | ||
![]() | ||
001 0511 | 100 | mg |
001 0512 | 500 | mg |
001 0513 | 1 | g |
meta-METHOXYTOPOLIN RIBOSIDE (MemTR) [6-(3-methoxybenzylamino)-9-β-D-ribofuranosylpurine]
MW 387.40; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 101565-95-1; C18H21N5O5 | ||
![]() | ||
001 0531 | 100 | mg |
001 0532 | 500 | mg |
001 0533 | 1 | g |
meta-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(3-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 417.43; crystallinE; purity > 95% (HPLC) | ||
S:26, 36; CAS: 1226978-27-7; C19H23N5O6 | ||
![]() | ||
001 5871 | 1 | mg |
001 5872 | 2 | mg |
001 5873 | 5 | mg |
para-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(4-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 417.43; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: NONE; C19H23N5O6 | ||
![]() | ||
001 5881 | 1 | mg |
001 5882 | 2 | mg |
001 5883 | 5 | mg |
trans-ZEATIN (tZ) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 219.25; crystalline; purity > 99% (HPLC); white crystalls; cis-isomer < 0.05% | ||
S:26, 36; CAS: 1637-39-4; C10H13N5O | ||
![]() | ||
001 0301 | 5 | mg |
001 0302 | 10 | mg |
001 0303 | 100 | mg |
001 0304 | 1 | g |
trans-ZEATIN HYDROCHLORIDE (tZ.HCl) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine hydrochloride]
MW 255.71; crystalline; purity > 97% (HPLC) | ||
R:22, S:36; CAS: 6025-81-6; C10H13N5O.HCl | ||
water soluble | ||
![]() | ||
001 5101 | 100 | mg |
001 5102 | 250 | mg |
001 5103 | 1 | g |
trans-ZEATIN RIBOSIDE (tZR) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 351.37; crystalline; purity > 99% (HPLC); white crystalls; cis-isomer < 0.05% | ||
S:26, 36; CAS: 6025-53-2; C15H21N5O5 | ||
![]() | ||
001 0311 | 5 | mg |
001 0312 | 10 | mg |
001 0313 | 100 | mg |
001 0314 | 1 | g |
ZEATIN mixed isomers (E/Z) equal mixture of cis- and trans- isomers [6-(4-hydroxy-3-methylbut-2-enylamino)purine]
MW 219.25; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 13114-27-7; C10H13N5O | ||
![]() | ||
001 3171 | 5 | mg |
001 3172 | 10 | mg |
001 3173 | 100 | mg |
001 3174 | 1 | g |
ZEATIN RIBOSIDE mixed isomers (E/Z) equal mixture of cis- and trans- isomers [6-(4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 351.37; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 28542-78-1; C15H21N5O5 | ||
![]() | ||
001 3181 | 5 | mg |
001 3182 | 10 | mg |
001 3183 | 100 | mg |
001 3184 | 1 | g |
trans-ZEATIN-7-GLUCOSIDE (tZ7G) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-7-b-D-glucopyranosylpurine]
MW 381.39; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 38165-56-9; C16H23N5O6 | ||
![]() | ||
001 5111 | 1 | mg |
001 5112 | 2 | mg |
001 5113 | 5 | mg |
trans-ZEATIN-9-GLUCOSIDE (tZ9G) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
MW 381.39; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 51255-96-0; C16H23N5O6 | ||
![]() | ||
001 0471 | 1 | mg |
001 0472 | 2 | mg |
001 0473 | 5 | mg |
trans-ZEATIN-9-GLUCURONIDE (tZ9GN)
MW 395.38; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: NONE; C16H21N5O7 | ||
![]() | ||
001 5961 | 5 | mg |
001 5962 | 10 | mg |
001 5963 | 50 | mg |
trans-ZEATIN-O-GLUCOSIDE (tZOG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)purine]
MW 381.39; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 56329-06-7; C16H23N5O6 | ||
![]() | ||
001 5121 | 1 | mg |
001 5122 | 2 | mg |
001 5123 | 5 | mg |
trans-ZEATIN-O-GLUCURONIDE (tZOGN)
MW 395.38; CRYSTALLINE; purity > 95% (HPLC) | ||
S:26, 36; CAS: 147663-51-2; C16H21N5O7 | ||
![]() | ||
001 5971 | 5 | mg |
001 5972 | 10 | mg |
001 5973 | 50 | mg |
trans-ZEATIN-O-GLUCOSIDE RIBOSIDE (tZROG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 513.51; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 62512-97-4; C21H31N5O10 | ||
![]() | ||
001 5131 | 1 | mg |
001 5132 | 2 | mg |
001 5133 | 5 | mg |
trans-ZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (tZMP) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 499.33; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 25615-16-1; C15H20N5Na2O8P.H2O | ||
![]() | ||
001 5141 | 1 | mg |
001 5142 | 2 | mg |
001 5143 | 5 | mg |
trans-ZEATIN-9-GLUCOSIDE-O-GLUCOSIDE (tZ9GOG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
MW 543.64; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 115921-05-6; C22H33N5O11 | ||
![]() | ||
001 5501 | 1 | mg |
001 5502 | 2 | mg |
001 5503 | 5 | mg |
trans-ZEATIN-O-ACETYL (ActZ) [6-((E)-4-acetoxy-3-methylbut-2-enylamino)purine]
MW 261.29; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 6025-82-7; C12H15N5O2 | ||
![]() | ||
001 5151 | 1 | mg |
001 5152 | 2 | mg |
001 5153 | 5 | mg |
2-CHLORO-trans-ZEATIN (2CltZ) [2-chloro-6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 253.69; crystalline; purity > 98% (HPLC) | ||
S:26, 36; CAS: 29736-30-9; C10H12ClN5O | ||
![]() | ||
001 5161 | 5 | mg |
001 5162 | 10 | mg |
001 5163 | 50 | mg |
2-METHYLTHIO-trans-ZEATIN (2MeStZ) [2-methylthio-6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 265.34; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 29736-33-2; C11H15N5OS | ||
![]() | ||
001 5171 | 1 | mg |
001 5172 | 2 | mg |
001 5173 | 5 | mg |
2-METHYLTHIO-trans-ZEATIN RIBOSIDE (2MeStZR) [2-methylthio-6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-b-D-ribofuranosylpurine]
MW 397.46; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 53274-45-6; C16H23N5O5S | ||
![]() | ||
001 5181 | 1 | mg |
001 5182 | 2 | mg |
001 5183 | 5 | mg |
cis-ZEATIN (cZ) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 219.25; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 32771-64-5; C10H13N5O | ||
![]() | ||
001 0321 | 5 | mg |
001 0322 | 10 | mg |
001 0323 | 50 | mg |
cis-ZEATIN RIBOSIDE (cZR) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-b-D-ribofuranosylpurine]
MW 351.37; crystalline; purity > 99% (HPLC) | ||
S:26, 36; CAS: 15896-46-5; C15H21N5O5 | ||
![]() | ||
001 0331 | 5 | mg |
001 0332 | 10 | mg |
001 0333 | 50 | mg |
cis-ZEATIN-9-GLUCOSIDE (cZ9G) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
MW 381.39; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 169565-72-4; C16H23N5O6 | ||
![]() | ||
001 2891 | 1 | mg |
001 2892 | 2 | mg |
001 2893 | 5 | mg |
cis-ZEATIN-O-GLUCOSIDE (cZOG) [6-((Z)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)purine]
MW 381.39; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 71866-93-8; C16H23N5O6 | ||
![]() | ||
001 3391 | 1 | mg |
001 3392 | 2 | mg |
001 3393 | 5 | mg |
cis-ZEATIN-O-GLUCOSIDE RIBOSIDE (cZROG) [6-((Z)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 513.51; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 125225-72-1; C21H31N5O10 | ||
![]() | ||
001 3251 | 1 | mg |
001 3252 | 2 | mg |
001 3253 | 5 | mg |
cis-ZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (cZMP) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 499.33; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 125225-71-0; C15H20N5Na2O8P.H2O | ||
![]() | ||
001 0591 | 1 | mg |
001 0592 | 2 | mg |
001 0593 | 5 | mg |
2-METHYLTHIO-cis-ZEATIN (2MeScZ) [2-methylthio-6-((Z)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 265.34; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 52020-11-8; C11H15N5OS | ||
![]() | ||
001 0541 | 1 | mg |
001 0542 | 2 | mg |
001 0543 | 5 | mg |
2-METHYLTHIO-cis-ZEATIN RIBOSIDE (2MeScZR) [2-methylthio-6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 397.46; crystalline; purity > 95% (HPLC) | ||
S:26, 36; CAS: 52049-48-6; C16H23N5O5S | ||
![]() | ||
001 0561 | 1 | mg |
001 0562 | 2 | mg |
001 0563 | 5 | mg |
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)